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ABSTRACT

Over the past few years, researchers have focused their attention on the development of
targeted cancer therapies to minimize the side effects associated with non-targeted treatments
such as chemotherapy. Specifically, these approaches have focused on blocking growth factor
receptors (GFR) that are overexpressed in cancer cells. In this thesis, we also focus on targeting
overexpressed GFR; however, instead of blocking the GFR, our novel approach aims at using
them to selectively enhance the endocytotic process of macropinocytosis to deliver peptides that
either disrupts the mitochondria or inhibits glycolysis.
Herein, we show the selective enhancement of macropinocytosis by the fusion protein
comprised of the keratinocyte growth factor (KGF) fused to elastin like polypeptide (ELP),
KGF-ELP. Furthermore, we report the synthesis of the fusion protein consisting of
mitochondriotoxic peptide (KLAKLAK)2 with ELP, (KLAKLAK)2-ELP. We show that
(KLAKLAK)2-ELP forms nanoparticles (NPs) that are internalized via macropinocytosis and
their internalization is facilitated by the interaction between the ELP domain and heparan sulfate
proteoglycan (HSPG) on the cell surface. This internalization results in mitochondrial swelling,
depolarization and subsequent cell death. Moreover, we show that heterogeneous NPs
comprising of the two fusions KGF-ELP and (KLAKLAK)2-ELP selectively kill lung cancer
cells expressing the keratinocyte growth factor receptor (KGFR).
We also report the synthesis of the fusion consisting of peptides derived from a
phosphorylated domain of the glycolytic enzyme phophoglycerate mutase (PGM) and ELP,

viii

PGM-ELP. We demonstrate that this fusion inhibits the step in glycolysis that converts 3phosphoglycerate (3PG) to 2-phosphoglycerate (2PG); the results show that cell death occurred
preferentially in lung cancer cells compared to normal cells. Additionally, the heterogeneous NPs
comprising of KGF-ELP and PGM-ELP selectively enhanced killing in lung cells with high
levels KGFR. Finally, the synthesis of a fusion proteins consisting of four PGM domains fused
to ELP, (PGM)4-ELP, exhibits higher cytotoxic effect and efficiency when compared to the
single PGM domain fusion, PGM-ELP.
Overall, we conclude that targeting overexpressed growth factor receptors to stimulate
macropinocytosis can be a tremendously selective therapy for the treatment of lung cancer. This
can result in attenuating side effects and improvement of the patient’s prognosis.

ix

CHAPTER 1: INTRODUCTION

1.1 The Lungs
The lungs are a pair of spongy organs located in the thoracic cavity where they are
protected by the rib cage. They are divided into lobes. The right lung consists of three lobes:
superior, middle and inferior. The superior and middle lobes are separated by a gap called the
horizontal fissure; the oblique fissure separates the middle and inferior lobes. The left lung is
smaller and comprised of only two lobes, superior and inferior, separated by an oblique fissure,
Figure 1.1.
The main function of the lungs is the oxygenation of blood and removal of carbon
dioxide (CO2). To achieve this gas exchange air travels deep into the lungs through structures
named air passages. First, air is inhaled through the nose or mouth, and then it continues to the
trachea, which splits into two branches, the bronchi. The air continues its path into smaller
branches of the bronchi called bronchioles, which end in air sacs called alveoli. The alveolus is
the site where gas exchange actually occurs. Capillaries cover the alveoli and bring blood that
has been depleted of oxygen (O2) and is rich is CO2 in contact with the alveoli which have high
concentration of O2 and low concentration of CO2. Because of the different in concentration, O2
diffuses into the blood stream while CO2 travels into the alveoli, Figure 1.2.
The oxygenation of blood is a very critical process; O 2 in the blood is delivered to all
different tissues in the body, cells in these tissues use it to produce energy in the form of ATP.
Life could not be sustained without O2. Just as important is the removal of CO2. This gas is a
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byproduct of respiration and its accumulation in the body can cause the blood to become acidic
Increase in the acidity of the blood can damage the function of vital organs such as the brain.
1.2 Lung Cancer
Lung cancer is the abnormal, uncontrolled growth of cells in the lungs, usually
originating from the epithelial cells in the air passages. This uncontrolled growth can result in the
formation of a mass of cells called a lung tumor. Tumors may remain at the site where they
originated in which case they are considered to be benign; contrastingly, tumors may also spread
to other parts of the body in which case they are identified as malignant. The spreading of cancer
cells over the body is termed metastasis and makes the treatment of any cancer very challenging.
The American Cancer Society recognizes three main types of lung cancers: Non-Small
Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Lung Carcinoid Tumors. The
frequency of each of these types of lung cancer varies considerably with NSCLC being the most
common with 85% prevalence, while SCLC and Lung Carcinoid Tumors only represent 15% and
5%, respectively [1]. Lung cancer is associated with factors that include smoking, exposure to
second hand smoking, exposure to chemicals such asbestos, and even air pollution [2].
There are more than one hundred types of cancer; among which, lung cancer is the
leading cause of death in the United States [3]. The American Cancer Society estimated 221,200
new cases and 158,040 deaths due to lung cancer in the year 2015. Lung cancer is responsible for
28% of cancer related deaths in the United States; this is more than the mortality rate of the next
four most common cancer types (colon, breast, prostate, pancreas) combined [4], Figure 1.3. In
addition, the 5-year observed survival rate is low; it varies from 49% to 1%. The variation
depends on the stage at which the cancer was detected.
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1.3 Stages of NSCLC
As discussed above, lung cancer is the uncontrolled growth of cells in the lungs.
Continued growth can result in the invasion of nearby tissues and organs. Furthermore, cancer
can expand to distant organs and tissues through the lymphatic system or the blood stream. The
characterization of this progression in size and spreading is called staging. Staging is important
because it allows the identification of proper treatment as well as the prognosis of the patient.
Staging can also determine if a patient is suitable to be part of a clinical trial. The following
stages are used for NSCLC: occult stage, stage 0, stage I (A and B), stage II (A and B), stage III
(A and B), and stage IV [5].
Briefly, the occult stage is the earliest stage at which NSCLC can be detected. In this
stage, cancer has not metastasized but remains in situ. Cancer cells can be found in the sputum.
In stage 0, abnormal cells can be found in the lining of the lungs. These cells are localized;
therefore, this stage is also called carcinoma in situ. In stage I, a tumor has formed. This stage is
further subdivided depending on the size and invasion. In stage IA, the tumor is less than 3 cm
while in stage IB the tumor is between 3 and 5 cm. and may have spread to the bronchus or may
have invaded the inner membrane that covers the lung.[5]. Stage II is characterized by the
spreading of the tumor to the lymph node located on the same side of the tumor. Furthermore,
stage IIA is characterized by a size that is less than 5 cm while stage IIB size is between 5 and 7
cm. In stage III, cancer can be of any size and spread to the lymph nodes of the same side of the
tumor. In addition in stage IIIA, other structures may have also been invaded such as the chest
wall, diaphragm, and the membrane around the heart. Similarly, in stage IIIB, cancer is present
in the lymph nodes and can be of any size. In addition to the structures that are invaded during
stage IIIA, in this stage the cancer may have also spread to the esophagus, the trachea, and the
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heart. In stage IV, cancer may have all the characteristics of the previous stages; in addition,
tumors will be present in both lungs. Moreover, the cancer has spread to various organs such as
the brain and the liver.
1.4 Common Lung Cancer Treatments for NSCLC
The treatment of choice for lung cancer as well as any other cancer depends on several
aspects: stage of cancer, patient’s health, side effects, and presence of other lung complications
such as bronchitis. The most common options for the treatment of lung cancer include surgery,
radiation therapy, chemotherapy, targeted therapy or a combination of the aforementioned.
1.4.1 Surgery
Lung surgery is very complex and is mainly limited to the removal of tumors that have
not metastasized. In addition, the patient’s health and lung functionality need to be addressed
before surgery can be conducted; therefore, surgery is not always an option. However, surgery
remains the best alternative to cure NSCLC. Studies have shown that surgery complemented
with chemotherapy and/or radiation therapy has further improved the outcome in early stages of
NSCLC [6]. Furthermore, after the removal of a lung mass by surgery, there is a 1% to 2% risk
of recurrence [7]. The types of lung surgery for the removal of a lung tumor include
segmentectomy, lobectomy, and pneumonectomy; the choice depends on whether part of a lobe,
a lobe or the entire lung needs removal, respectively.
1.4.2 Radiation Therapy
This type of therapy involves the use of ionizing radiation such as x-rays or gamma rays.
Radiotherapy can be used as a primary treatment or an adjuvant treatment. The main goal
radiation therapy is to shrink tumors and/or kill cancer cells. Similar to surgery, the use of
radiation therapy is limited to localized tumors. In addition, there are limits to the amount of
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radiation lungs and other organs can be exposed to without causing irreversible damage. This
therapy however offers an alternative for stage I NSCLC patients for whom surgery is not an
option. Studies have suggested that this type of therapy may have cure rates equivalent to surgery
in stage I patients [8].
1.4.3 Chemotherapy
Chemotherapy consists of the use of anti-cancer drugs; the function of these drugs is
mainly targeting fast dividing cells. Contrary to surgery and radiation therapy that are commonly
used when the cancer is localized, chemotherapy can act throughout the body, which allows for
the treatment of cancer that has already metastasized. However, this inherent characteristic of
chemotherapeutic drugs can also affect non-cancerous cells that divide quickly such as red blood
cells and epithelial cells lining the intestines. Therefore, even though chemotherapy is commonly
used to treat lung cancer, it involves the indiscriminate killing of normal, healthy cells resulting
in side effects. Furthermore, the development of resistance to chemotherapeutics often occurs,
making this therapy, in many cases, ineffective over a period of time. Several chemotherapeutic
drugs have been developed, they include DNA damaging drugs such as cisplatin or doxorubicin,
and mitotic inhibitors such as paclitaxel [9]. However, due to significant side effects such as
nephrotoxicity that may result from its nonspecific systemic organ distribution and inadequate
intratumor concentrations, researchers are developing therapeutic agents that selectively affect
tumor cells, targeted therapy.
1.4.4 Targeted Therapy
The goal of targeted therapy is to minimize side effects associated with the unselective
killing of cells due to chemotherapeutics. Targeted therapy exploits differences between normal
and cancerous cells. One of the most popular targets for lung cancer is the epidermal growth
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factor receptor (EGFR) that is overexpressed in 50 % to 90 % of lung cancers [10, 11].
Consequently, monoclonal antibodies against the EGFR (cetuximab) and tyrosine kinase
inhibitors (TKI) that inhibit the tyrosine kinase activity of EGFR (erlotinib or gefitinib) have
been developed and have shown mixed results in the treatment of lung cancer in several clinical
trials [9]. Although, TKIs show good response rates in lung cancer patients, acquired resistance
to TKI treatment always develops after a median of 10 months from the initiation of treatment
[12]. This acquired resistance can be attributed to several factors such as secondary mutation of
the EGFR gene, amplification of the MET gene or overexpression of HGF [12]. The issue of
acquired resistance is present not only in TKI treatment but in all other chemotherapy treatments
as well, since tumor cells bypass the pathways that these drugs target; rendering the drugs
ineffective. Therefore, patient prognosis still remains poor with 5-year survival rate of less than
5% and a median survival of approximately 1 year.
1.5 Novel Strategy for Targeting NSCLC Cells
Current targeted therapies aim at blocking growth factor receptors to prevent cells from
proliferating and growing. The problem faced by this strategy is that cancer cells are highly
mutagenic and a minimal change in the target renders the therapy ineffective. In this thesis, we
look into a novel strategy that takes advantage of overexpressed growth factor receptor and use
them to selectively enhance the endocytotic mechanism of macropinocytosis (chapter 3). This
stimulation occurs through the activation of the keratinocyte growth factor receptor (KGFR),
which has been reported to be overexpressed in lung cancer [13, 14]. Furthermore, this activation
is used to deliver a mitochondriotoxic peptide (Chapter 3) or a glycolytic inhibiting peptide
(Chapter 4) to KGFR overexpressing cells.
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1.6 Summary
Lung cancer is the leading cause of death among all the different cancer types, being nonsmall cell lung cancer (NSCLC) the most common with an 85% incidence. There are different
options for the treatment of this type of cancer including surgery, radiotherapy, chemotherapy,
targeted therapy, and a combination of the aforementioned. The treatment of choice depends on
various aspects such as stage of the cancer and health of the patient. Although much progress has
been achieved in the treatment of lung cancer, the 5-year survival rate remains as low as 5% with
a median survival of approximately 1 year. Furthermore, the issue of acquired resistance and the
recurrence of the cancer seem to be a common theme regardless of the treatment of choice.
Altogether, there is a clear need for further research and development of novel therapies for the
treatment of lung cancer.

Figure 1.1 Anatomy of the lung and related structures [15].
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Figure 1.2 Gas exchange in the alveoli [16].

Figure 1.3 Mortality rates of different cancer types [1].
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CHAPTER 2: (KLAKLAK)2 -ELP CAUSES APOPTOSIS THROUGH
MITOCHONDRIAL DEPOLARIZATION

2.1 Note to Reader
Part of this chapter was published in Medical Oncology: R. Iglesias and P. Koria,
"Leveraging growth factor induced macropinocytosis for targeted treatment of lung cancer," Med
Oncol, vol. 32, p. 259, Dec 2015. Permission is included in Appendix B.
2.2 Introduction
KLAKLAKKLAKLAK, (KLAKLAK)2, is a peptide that disrupts the outer mitochondrial
membrane once uptaken by cells. However, cells are impermeable to it; therefore, its cytotoxic
effect in mammalian cells is hindered. In this chapter we show that the fusion comprising of
(KLAKLAK)2 and elastin like polypeptide (ELP), (KLAKLAK) 2-ELP, is internalized by cells.
Surprisingly, the functionalization of the fusion was not required as others have suggested.
Furthermore, the fusion retains the self-assemble property of ELPs and the bioactivity of
(KLAKLAK)2; therefore, the fusion causes mitochondrial depolarization. We also show that the
ELP domain of the fusion interacts with heparan sulfate proteoglycan (HSPG) on the cell
surface. Moreover, we establish that (KLAKLAK) 2-ELP is internalized by the transient,
endocytotic mechanism of macropinocytosis.
2.3 Elastin Like Polypeptide (ELP)
Elastin like peptides (ELPs) are biodegradable, non-immunogenic protein-based
polymers composed of tandemly repeated blocks of (Val-Pro-Gly-X-Gly)N where X can be any
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residue but Pro [1-3]. This sequence motif is derived from the hydrophobic domain of
tropoelastin, a soluble precursor form of elastin. An interesting property of ELPs is their ability
to undergo a phase transition at physiological temperatures [4, 5]. When the temperature is below
their inverse transition temperature, also known as the lower critical solution temperature
(LCST), they assume a random coil structure and are soluble in aqueous solution. However, at
temperatures higher than the LCST, ELPs undergo an entropy driven self-assembly rendering
them insoluble. This property enables recombinant ELPs to be expressed in bacteria and rapidly
purified to high homogeneity using inverse temperature cycling (ITC) [2, 6]. Since ELPs are
genetically encodable, biologically active peptides or proteins can be genetically fused to ELPs.
These fusions can be expressed and readily purified since they maintain the phase transitioning
property of the fused ELP domain. Moreover, owing to the transition property of ELPs, the
chimeric fusion proteins can self-assemble into nanoparticles [7, 8]. Finally, the biological
activity of the fused moiety in the chimeric fusion is retained [9, 10].
2.4 Mitochondriotoxic Peptide (KLAKLAK)2
(KLAKLAK)2, is a synthetic 14-amino acid peptide whose structure was designed to
mimic natural occurring antimicrobial peptides [11]. These peptides are usually characterized by
their positive charge as well as their alpha helix structure [12]. Their selective antimicrobial
action is attributed to the difference in overall membrane charge between bacterial and
mammalian cells; bacterial membranes have an overall negative charge while mammalian cells
are neutral. This translates to the higher transmembrane potential observed in bacterial cells. This
same high transmembrane potential is also noted in the mitochondria, an organelle the main
function of which is the production of energy through the electron transport chain (ETC). The
ETC consist of a series of molecules whose main function is the creation of a proton gradient
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which drives the production of ATP. Among those molecules that are part of the ETC is
Cytochrome c (cyt c). Cyt c is a small molecule that when released to the cytoplasm causes cell
death, apoptosis.
(KLAKLAK)2 is an amphipathic molecule that has a high positive charge, it has been
shown to interact with the mitochondria causing swelling and mitochondrial depolarization [13].
Its mode of action is speculated to be through the creation of pores on the outer mitochondrial
membrane that disrupts the proton gradient resulting in swelling and eventual release of cyt c
[14, 15]. For (KLAKLAK)2 to be effective, it must be internalized; however, mammalian cells
are impermeable to (KLAKLAK)2. Previous works have demonstrated that when (KLAKLAK) 2
is part of a nanostructure, cells become more permeable to it [16, 17]. Therefore, we reasoned
that creating the fusion (KLAKLAK) 2-ELP would result in its internalization by taking
advantage of the ELP phase transition characteristic above its T t.
2.5 Fusion (KLAKLAK)2-ELP
2.5.1 Materials and Methods
2.5.1.1 Materials
Fetal bovine serum (FBS) and Dulbecco modified Eagle Medium (DMEM) were
purchased from Life Technologies. The restriction enzymes and other enzymes used for cloning
were purchased from New England Biolabs (Ipswich, MA). Dr. Haura from Moffit Cancer
Center kindly donated A549 and HCC827 cells. The apoptotic peptide gene and ELP gene were
purchased from GenScript (Piscataway, NJ). The miniprep and gel extraction kits were
purchased from QIAGEN.
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2.5.1.2 Synthesis of (KLAKLAK)2-ELP
The PUC57 plasmids containing the genes (VPGVG)5 , (VPGVG)2VPGCG(VPGVG)2
and (KLAKLAK)2 were purchased from Genscript (Piscataway, NJ). The V40C2 encoding gene
was made using the recursive direction ligation method as described previously [18]. The
(KLAKLAK)2 gene was excised using PflMI and Bgll enzymes. These genes were then run on a
0.08% agarose gel and extracted using a QIAquick Gel Extraction Kit. PflMI linearized the
pUC19 vector containing the ELP sequence and the excised (KLAKLAK)2 gene was cloned in
frame with the ELP gene. This resulted in the pUC19 vector containing the (KLAKLAK)2-ELP
fusion protein gene flanked by pfIMI and BgII sites. The sequences encoding for the fusion
proteins were then removed from the pUC19 vector using pflMI and BgII enzymes and
recovered by gel extraction as explained above. After extraction, these genes were cloned in a
modified pET25b+ expression vector through SfiI site. This vector was modified to incorporate
an SfiI cloning site for the cloning of the fusion protein.
The pET25b+ vector containing the fusion protein gene was transformed into BLRD
competent cells through heat shock at 42 oC. A starting culture of 50 ml was inoculated overnight
and added to a 1 L culture the next day. The 1 L culture was then grown overnight and
subsequently purified by inverse transition cycling as described previously [19]. Figure 2.1
shows a representation of the genes for (KLAKLAK)2 and ELP and the production of the fusion
(KLAKLAK)2-ELP. Also, the illustration of the thermoresponsive property of the synthesized
fusion above and below its Tt is represented.
2.5.1.3 Cell Culture
Cells were cultured in a humidified incubator at 370C and 5% CO2. Cells were seeded on
24 or 48-well plates until they were approximately 70% confluent. A549 and HCC827 (human
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lung carcinoma) were grown in DMEM supplemented with 10% FBS and 1% AA (Complete
Medium).
2.5.1.4 Dynamic Light Scattering of (KLAKLAK)2-ELP
Lyophilized (KLAKLAK)2-ELP was resuspended in PBS to a final concentration of 50
μM. The solution was filter using a 220 μm filter and transfer to a cuvette. The analysis was
performed using Zetasizer Nano S at different temperatures (20 oC and 37 oC).
2.5.1.5 Transmission Electron Microscopy of (KLAKLAK)2-ELP
Lyophilized (KLAKLAK)2-ELP was diluted in PBS to a final concentration of 50 μM.
Enough solution was added to a carbon-coated grid to cover its surface. The grid was placed on
an incubator at 37 oC for the (KLAKLAK)2-ELP to form nanoparticles. Once adsorbed on the
grid, the particles were stained with uranyl formate staining solution and analyzed at Electron
Microscopy Core Lab in the Interdisciplinary Science Building at the University of South
Florida.
2.5.1.6 Mitochondrial Swelling
Cells (HCC827) were treated for 24 Hrs. with 50 μM of (KLAKLAK)2-ELP. After the
treatment, cells were fixed with 2.5% glutaraldehyde in 100 mM phosphate buffer at pH 7.
Following fixation, standard embedding protocol for resin section was followed. TEM imaging
was performed at Electron Microscopy Core Lab in the Interdisciplinary Science Building at the
University of South Florida.
2.5.1.7 Mitochondrial Depolarization Assay
Cells (10,000/well) were seeded on 48-well plates using fresh complete media. After 24
hours, cells were treated with the indicated treatment of (KLAKLAK)2-ELP or (KLAKLAK)2
peptide. A JC-1 assay kit (Life Technologies cat # M34152) was used for mitochondrial
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depolarization analysis. After treatment, media was removed and cells were washed with icecold PBS. JC-1 was added to fresh media to a final concentration of 2uM and this was added to
the cells for 1 hour after which media was removed and cells were washed with ice-cold PBS
before fluorescent pictures were taken (10X magnification) using EVOS fluorescence
microscope (Life technologies). For the positive control sample, Carbonylcyanide mchlorophenylhydrazone (CCCP) to a final concentration of 50 uM was added simultaneously
with JC-1.
Mitochondrial depolarization analysis was also performed using flow cytometry. Cells
(50,000/well) were seeded on 24 well plates and let grow to about 70% confluency; after which,
they received no treatment, CCCP treatment or (KLAKLAK) 2-ELP treatment.; one sample
(assay control) was used for gating purposes. The CCCP treatment was added 30 minutes before
analysis. After (KLAKLAK)2-ELP treatment for 24 hours, cells were washed with PBS and
trypsinized (0.25 % trypsin). Trypsin was removed by centrifugation (800 rpm) and cells were
resuspended in 300 μl of PBS. To exclude non-viable cells, 4',6-diamidino-2-phenylindole
(DAPI) was added to the samples before analysis. Cells were analyzed using flow cytometry and
the intensity in the red (PI) and green (FITC) channels were reported.
2.5.1.8 Labeling of the Fusion Proteins
The cysteines present in the ELP sequence were labeled using maleimide chemistry for
the particle internalization experiments. Fluorescein-5-maleimide (AnaSpec Inc cat # 81405) was
mixed with the fusion proteins. The mixture was placed on an orbital shaker and incubated at
room temperature for 2 hours. Unconjugated fluorescein was removed by a series of hot and cold
cycles on a bench top centrifuge ran at a speed of 20000g for 10 minutes each time. The
supernatant was discarded after the hot spin and an equal amount of cold sterile PBS was added.
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This mixture was spun at 4 0C and the supernatant was collected while the pellet was discarded.
This formed one complete cycle of inverse temperature cycling. To get rid of all the
unconjugated fluorescein, at least 5 cycles were performed.
2.5.1.9 Fusion Protein Internalization Assay
Cells (50,000/well) were seeded in 24-well plates and cultured as described above. They
were let grow until they were about 70% confluent and were treated with the indicated
treatments. For analysis, cells were washed twice with ice-cold PBS and were trypsinized using
0.25% trypsin (100 μl). Cells were pelleted and re-suspended in 300 μl of PBS containing 50
-diamidino-2phenylindole (DAPI) to allow exclusion of nonviable cells. The cells were analyzed using flow
cytometry and either the percent of fluorescent cells or the average intensity was quantified and
reported.
Some wells were pre-treated for 30 minutes with either inhibitors of macropinocytosis
(amiloride and wortmannin) or receptor-mediated endocytosis (chlorpromazine). After the pretreatment, cells were treated with the indicated labeled fusion proteins and internalization was
measured by flow cytometry as described above. The inhibitor concentrations were used as
described previously [20]

heparan sulfate proteoglycans (HSPG) or the elastin receptor, cells were pre-treated with either
20mIU/ml) or lactose (5 mM).

17

2.5.1.10 Live/Dead Assay
Cells were seeded and treated with the indicated treatments for 3 days. After their
respective treatments, ethidium homodimer-1 (Life Technologies cat # E1169) was added to
each well to a final concentration of 4uM. Cells were then incubated for 1 hour at 37 oC. After the
incubation time, cells were washed twice with PBS to remove floating cells. NucBlue (Life
Technologies R37605) was then added for 20 minutes to stain nuclei, followed by two washes
with PBS. Eight random pictures were taken per well using the EVOS fluorescence microscope
(10X magnification). Pictures were taken in different channels (blue, green, red) and overlay.
Live/dead cell discrimination was performed using image J. A macro was created using the
functions split channel, threshold, and cell counter to count the total number of live cells (blue)
in each picture. Dead cells that were not removed after the washes were stained red or magenta
(blue and red); adjusting the threshold for the picture being analyzed easily isolated these cells.
Therefore, the final count of cells per picture only included live cells.
2.5.1.11 Statistical Analysis
For statistical significance, the p value was calculated using ANOVA single factor. P
values < 0.05 were considered significant. The reported errors indicate the ±SEM.
2.5.2 Results
2.5.2.1 (KLAKLAK)2-ELP Preserves the Phase Transition Property of ELPs
ELPs are genetically encodable; therefore, they are relatively easy to functionalize using
simple recombinant DNA technology techniques. In addition, ELPs’ phase transition property
makes them very appealing for the synthesis of nanoparticles that are thermoresponsive and
allow for improve concentration of treatment to a site that has been exposed to a temperature that
is equal to or higher than the ELP Tt [10, 21, 22] Many studies have shown that ELPs greatly
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preserve this phase transition property when fused to other domains [23, 24]. Based on these
studies, we tested if our fusion (KLAKLAK) 2-ELP preserve the self-assemble property of ELPs.
Our results clearly showed that (KLAKLAK) 2-ELP is in its soluble form at a temperature of 20
oC

while it aggregates to a size of about 350 nm at a temperature of 37 oC (Figure 2.2). Since

these experiments were carried out as a cycle, with one cycle consisting of increasing and
decreasing the temperature from 20 oC to 37 oC and back, we concluded that the ELP selfassemble property was retained. TEM further confirmed the size of the (KLAKLAK) 2-ELP
aggregate to be about 350 nm (Fig 2.3).
2.5.2.2 (KLAKLAK)2-ELP Causes Mitochondrial Swelling
Previous work has shown that (KLAKLAK)2 causes mitochondrial swelling through the
disruption of the outer mitochondrial membrane [13]. We wanted to confirm that our fusion
(KLAKLAK)2-ELP had the same toxic effect in cells. TEM analysis of our samples clearly
indicated a difference between the mitochondria of the control compare the mitochondria of the
(KLAKLAK)2-ELP treated sample (Figures 2.4 and 2.5). Therefore, we concluded that the mode
of action of our fusion is similar to the (KLAKLAK) 2 peptide.
2.5.2.3 (KLAKLAK)2 Fused to ELPs Induces Cell Death Via Mitochondrial Depolarization
Previous studies have shown that (KLAKLAK) 2 has low mammalian cell toxicity but can
induce mitochondrial depolarization and subsequent apoptosis when fused to a homing domain
[11, 13]. Furthermore, others have demonstrated that when (KLAKLAK)2 is part of a
nanostructure that is functionalized with a cell penetrating peptide (CPP), it is internalized and
causes cell death [16, 17]. Based on these findings, we fused (KLAKLAK) 2 to elastin like
peptides (ELP), (KLAKLAK)2-ELP, making it possible to form nanostructures as mentioned
above. Surprisingly, after a 48-hour treatment, (KLAKLAK)2-ELP caused 30%, 85%, and 93%

19

of cell death at 20μM, 50μM and 100μM, respectively, without the need of a functionalizing
domain. Moreover, the same treatment with the (KLAKLAK) 2 peptide did not affect cell
viability (Figure 2.6). To further test if cell death occurred due to mitochondrial depolarization as
previously reported, we performed a JC-1 assay that distinguishes between healthy and
depolarized mitochondria. This assay stains healthy mitochondria in red and depolarized
mitochondria in green. After a 24 Hr. treatment with the (KLAKLAK)2-ELP fusion, cells
displayed the presence of depolarized mitochondria, (Figures 2.7 and 2.8). Combined, these
results suggest that the (KLAKLAK)2-ELP nanostructure caused cell death through
mitochondrial depolarization even in the absence of a functionalized domain.
2.5.2.4 Internalization of (KLAKLAK)2-ELP is Assisted by HSPG on the Cell Surface
Since the lack of a functionalizing domain in (KLAKLAK)2-ELP still resulted in cell
death, we reasoned that ELPs might be involved in the uptake of (KLAKLAK)2-ELP. Previous
works have found that ELPs interact with the elastin receptor [25]. Furthermore, tropoelastin
from which ELPs are derived interacts with HSPG on the cell surface [26]. Thus, we
hypothesized that the internalization of (KLAKLAK)2-ELP could also be mediated by the
interaction between the ELP portion of the fusion and one of these aforementioned molecules.
To test this hypothesis, we carried out experiments in the presence of molecules that block the
elastin receptor (lactose), cleave HSPG (heparinase III) or serve as a HSPG antagonist (surfen)
[27]. First, cells were pretreated with lactose that binds to the elastin receptor preventing other
molecules from binding to it. The presence of lactose did not affect the internalization of
(KLAKLAK)2-ELP (Figure 2.9) suggesting that the elastin receptor is not involved in the
internalization. Second, we pretreated the cells with heparinase III that cleaves HSPG from the
cell surface. Our results showed a 70% decrease in (KLAKLAK)2-ELP internalization when
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compared to control (Figure 2.9). Finally, to further confirm that HSPG was involved in
(KLAKLAK)2-ELP internalization, cells were pretreated with surfen, which is a small molecule
antagonist to HSPG [27]. The result showed that about 90% of (KLAKLAK)2-ELP
internalization was blocked (Figure 2.9). Thus, these results clearly indicate that the
internalization of (KLAKLAK)2-ELP depends on its interaction with HSPG.
2.5.2.5 (KLAKLAK)2-ELP is Internalized by Macropinocytosis
To gain insight into the mechanism of uptake of (KLAKLAK)2-ELP aggregates, we used
known blockers for two major endocytotic pathways. Chlorpromazine was used to block clathrin
mediated endocytosis, amiloride and wortmannin to block macropinocytosis. Internalization
experiments were carried out in the presence of each of these blockers using concentrations
previously determined [20]. The results showed that (KLAKLAK)2-ELP uptake was not affected
by chlorpromazine; however, amiloride and wortmannin decreased (KLAKLAK) 2-ELP
internalization by 70% and 75% , respectively (Figure 2.10). Altogether, these results indicate
that macropinocytosis is the major mechanism involved in (KLAKLAK) 2-ELP internalization.
2.6 Discussion and Summary
The mitochondriotoxic peptide (KLAKLAK) 2 is well known to disrupt the outer
mitochondrial membrane causing swelling and mitochondrial depolarization; this translates to
cell death. However, as demonstrated by others and us, cells are impermeable to (KLAKLAK)2;
therefore, it has not cytotoxic effect unless it is uptaken by cells. Other groups have reported
various strategies to improve (KLAKLAK) 2 internalization by cells such as fusing it to cell
penetrating peptides (CPP). Also, previous work suggested that (KLAKLAK) 2 internalization
can be improved by making it part of a nanoparticle in addition to functionalizing it with a CPP.
Based on the latter, we synthesized (KLAKLAK) 2-ELP, the ELP portion of the fusion provides
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the nanoparticle backbone when expose to a temperature higher than its Tt.. Interestingly, we
found that functionalization of the (KLAKLAK) 2 was not needed to improve its uptake, but the
nanoparticle formation was enough for its internalization and subsequent cell death.
Furthermore, we

show that

(KLAKLAK) 2-ELP

causes mitochondrial swelling and

depolarization; this is consistent with previously reported data. Therefore, our results clearly
indicate that the cytotoxic mechanism of (KLAKLAK) 2-ELP follows that of (KLAKLAK)2
peptide.
We found that the predominant mechanism of uptake of (KLAKLAK) 2-ELP
nanoparticles by cells was macropinocytosis. Tumor cells exhibit higher levels of
macropinocytosis than the normally quiescent non-cancerous cells [28, 29]. Thus,
macropinocytosis on its own may provide certain level of selectivity towards killing of cancer
cells. Indeed, it was observed that (KLAKLAK)2 nanoparticles demonstrated certain level of
killing selectivity towards cancer cells [17]. Though, the mechanism of internalization was not
reported in that study it is plausible that those nanoparticles were also being internalized by
macropinocytosis thereby explaining the selectivity.
We also show that the internalization of ELP nanoparticles was dependent on their
interaction with cell surface heparan sulfate proteoglycans (HSPG). This is in agreement with
previous studies that have reported that tropoelastin from which ELPs are derived interacts with
cell surface HSPG [26, 30]. The interaction of ELPs with HSPG may ensure proximity of the
NPs to the cell surface where they will be uptaken by macropinocytosis. Interestingly, previous
work has reported the importance of phase transition for the internalization of ELP based
molecules [31]. Our data may explain this observation because during phase transition ELPs
form β-strand structure, which has been reported as a common secondary structure for variety of
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proteins that interact with cell membrane bound HSPG [32]. Thus, the phase transition allows
ELPs to interact with HSPG facilitating its internalization.
In summary, we found that the fusion (KLAKLAK) 2-ELP is mitochondriotoxic without
the need to be functionalized; the nanoparticle conformation provided by the ELP backbone was
enough to cause the internalization and cytotoxicity of the fusion. Furthermore, cell death occurs
via mitochondrial depolarization and swelling. We found that the mechanism of internalization
of (KLAKLAK)2-ELP is macropinocytosis; we believe the interaction between the ELP domain
of the fusion and heparan sulfate on the cell membrane allows for the proximity required for
macropinocytosis to act on the (KLAKLAK)2-ELP nanoparticles
Table 2.1 (KLAKLAK)2 and ELP amino acid sequences.
(KLAKLAK)2

KLAKLAKKLAKLAK

ELP

V40C2

V

VPGVG

C

(VPGVG)2-VPGCG-(VPGVG)2
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Figure 2.1 Representation of (KLAKLAK)2-ELP synthesis and its thermoresponsive property.
Top, representation of (KLAKLAK)2 gene, the ELP, and their translation to the fusion
(KLAKLAK)2-ELP. Bottom, illustration of the phase transition property of the fusion above and
below its transition temperature (Tt). The fusion is soluble below its Tt and aggregates above its
Tt.
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Figure 2.2 Characterization of (KLAKLAK)2-ELP by dynamic light scattering. (KLAKLAK)2ELP retains the self-assemble property of ELPs. Lyophilized (KLAKLAK)2-ELP resuspended in
PBS to a final concentration of 50 μM was analyzed by DLS at 20 oC and 37 oC.. The graph
shows clearly two peaks at about 5 nm and 350 nm representing the (KLAKLAK)2-ELP as
unimers and as aggregates, respectively.
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Figure 2.3 TEM of (KLAKLAK)2-ELP. This fusion protein aggregates to a size of about 360 nm
as confirmed by TEM. (KLAKLAK)2-ELP was adsorbed on a carbon-coated grid, incubated at
37 oC and stained with uranyl formate. Bar = 200 nm.
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Figure 2.4 TEM of normal mitochondria. HCC827 were imaged by TEM. Red arrows show the location of the mitochondria.
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Figure 2.5 TEM of mitochondrial swelling. HCC27 cells were treated with 50 μM of (KLAKLAK)2-ELP for 24 Hrs. Cells were then
imaged by TEM. Red arrows indicate the location of the elongated mitochondria.
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Figure 2.6 Cytotoxic effect of (KLAKLAK)2-ELP and (KLAKLAK)2 peptide. (KLAKLAK)2ELP induces cell death at high concentrations while the (KLAKLAK)2 peptide does not. Lung
adenocarcinoma cells, A549, were treated for 48 Hrs. with different concentrations of
(KLAKLAK)2-ELP or (KLAKLAK)2 peptide. The percent of live cells was calculated using a
live/dead assay; pictures were then taken using a fluorescent microscope and the counting was
done using image J. All the treatments were normalized to the control (no treatment).
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Figure 2.7 Mitochondrial depolarization analysis by flow cytometry. A549 cells were treated for
24 Hr. with 10μM of (KLAKLAK)2-ELP or 30 min. with a known mitochondrial depolarizer,
CCCP. A JC-1 assay, which distinguishes between healthy and depolarized mitochondria, was
then performed. Analysis was carried out by flow cytometry. The assay control is for gating
purposes; the negative control consisted of untreated cells. The apoptotic label shows the area
where cells with depolarized mitochondria are found while the non-apoptotic label shows the
area where cells with healthy mitochondria are found. The results clearly show the
mitochondriotoxic effect of (KLAKLAK)2-ELP. PI-A and FITC-A refer to red and green
fluorescent channels, respectively.
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Figure 2.8 Mitochondrial depolarization analysis by fluorescent microscopy. Cells were treated with either 10 μM of (KLAKLAK)2ELP or CCCP diluted to a final concentration of 50 μM. The control consisted of untreated cells. Mitochondria are stained red
(healthy) or green (depolarized). The results clearly show that the fusion (KLAKLAK)2-ELP causes mitochondrial depolarization. Bar
= 400μm.
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Figure 2.9 (KLAKLAK)2-ELP internalization after blocking the elastin receptor complex and
heparan sulfate proteoglycan. A549 cells were pretreated with lactose, Heparinase III, or surfen
for 30 minutes, except for control. These cells were then treated with 10μM of labeled
(KLAKLAK)2-ELP for 24 Hrs. The percent of cells uptaking the treatment was quantified by
flow cytometry. To make sure that only internalized (KLAKLAK)2-ELP was quantified, trypan
blue was added to the cell suspension before analysis to quench any labeled molecule bound to
the cell surface. This experiment was repeated two times with triplicates. * indicates p < 0.05
when compared to control.
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Figure 2.10 (KLAKLAK)2-ELP internalization after blocking receptor mediated endocytosis and
macropinocytosis. A549 cells were pretreated with chlorpromazine (receptor-mediated
endocytosis blocker), wortmannin or amiloride (macropinocytosis blockers) for 1 Hr. The cells
were then treated with 10μM of labeled (KLAKLAK)2-ELP for 24 Hrs. in the presence of the
blockers before analysis by flow cytometry. Trypan blue was added to the cell suspension before
analysis to prevent including particles that may be bound to the cell surface. This experiment was
repeated two times with triplicates. * indicates p < 0.05 when compared to control. Error bars
represent ±SEM.
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CHAPTER 3: KGF-ELP ENHANCES MACROPINOCYTOSIS IN KGFR
OVEREXPRESSING CELLS

3.1 Note to Reader
Part of this chapter was published in Medical Oncology: R. Iglesias and P. Koria,
"Leveraging growth factor induced macropinocytosis for targeted treatment of lung cancer," Med
Oncol, vol. 32, p. 259, Dec 2015. Permission is included in Appendix B
3.2 Introduction
In this chapter we show that the fusion of the keratinocyte growth factor (KGF) and
elastin like polypeptide (ELP), KGF-ELP, selectively enhances macropinocytosis in keratinocyte
growth factor receptor (KGFR) overexpressing cells. Furthermore, we demonstrate that this
selectivity can be further used to improve the internalization of the fusion (KLAKLAK)2-ELP
discussed in the previous chapter. Finally, the heterogeneous nanoparticle comprising of KGFELP and (KLAKLAK)2-ELP clearly improves the cytotoxic effect of (KLAKLAK) 2-ELP in
KGFR overexpressing lung cancer cells.
3.3 Keratinocyte Growth Factor (KGF)
Growth factors are proteins whose functions include cell proliferation, migration, and
differentiation [1]. The mode of action of these molecules is through their interaction with their
receptor on the cell surface. Once this interaction occurs, intracellular signaling occurs that
permits the cell to undergo several changes resulting in the functions mentioned above.
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Much emphasis has been placed on growth factor receptors as target for cancer
treatment.[2-4] It is well known that a common characteristic of several cancer types is the
overexpression of growth factor receptors such as the epidermal growth factor receptor (EGFR)
[5, 6] and the keratinocyte growth factor receptor (KGFR) [7-9]. Therefore, one method used for
targeted treatment has aimed at blocking the extracellular domain of these receptors using
monoclonal antibodies (mAb); so that, the ligand/receptor interaction is loss and proliferation is
halted [10]. However, mAb are highly specific and a minor change in their target makes them
ineffective. Another way that has been used to target receptors is the use of small molecules that
block the intracellular domain of the receptors so that signaling pathways are not activated when
the ligand/receptor binding occurs [11]. However, the highly mutagenic nature of cancer cells
can develop an alternative pathway rendering the treatment unproductive.
Others have looked at the interaction between growth factor and its receptors as an
opportunity to selectively deliver cytotoxic cargo to cells overexpressing a receptor. For instance,
once the ligand/receptor interaction occurs, the process of receptor mediated endocytosis (RME)
initiates [12]. In addition, another internalization process that has been recently gaining more
interest is macropinocytosis [13]. This transient process can also be activated or enhanced by
growth factors and offers several advantages when compared to RME. For instance,
macropinocytosis allows for the uptake of several molecules on the cell periphery while RME is
limited to molecules that are in the areas where the interaction occurs.
One of the most common targets in lung cancer is the EGFR. The downside of targeting
EGFR is that it is ubiquitously express; thus, it is likely that targeting this receptor results in
unwanted systemic toxicity due to its stimulation in normal tissue. KGFR has been identified as
another receptor that is overexpressed in lung cancer [8, 14]. The advantage of using this
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receptor over EGFR is that KGFR is not expressed ubiquitously; therefore, systemic toxicity may
be diminished. Based on this, we opted to target KGFR. However, due to the simplicity of the
system we describe in this chapter, other growth factor receptors can easily be targeted such as
HGF [15] and EGF [16].
3.4 Macropinocytosis
Endocytosis is a process through which cells internalize nutrients, hormones, proteins,
and lipids that are required for diverse cell functions such as their proliferation, growth and
health maintenance. The vesicles formed during endocytosis fuse with endosomes for cargo
sorting and then either recycle back to the cell membrane and their contents expelled out from
the cell or they can fuse with lysosomes for subsequent degradation of the cargo. Endocytosis
can be subdivided into clathrin-dependent and clathrin-independent endocytosis depending on
whether the protein clathrin coats or not the formed vesicles, (Figure 3.1).
Clathrin-dependent endocytosis is also known as receptor mediated endocytosis (RME).
It is the most studied and understood endocytotic mechanism. One major characteristic RME is
that it internalizes macromolecules selectively. In addition, this process requires the interaction
between a ligand and its cell membrane receptor; these receptors are found on regions called
clathrin-coated pits. Upon ligand-receptor interaction, closure of these pits result in the formation
of vesicles that are coated with the protein clathrin making them leak-proof; therefore, the cargo
does not diffuse into the cytoplasm. As mentioned above however, these vesicles will fuse with
endosomes for sorting of their contents and eventual recycle or degradation by lysosomes.
Many studies have focus on the use of RME as a targeted delivery mechanism for drugs
to treat cancer. However, due to innate characteristics of this mechanism, it also provides many
challenges for its use. Other works have reported endosomal entrapment of their drugs [17-19].
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This occurs because of the leak proof vesicles formed during RME do not permit the diffusion of
the drugs into the cytoplasm, lowering or preventing the efficacy of the treatment due its low
intracellular concentration. Another limitation is the size constraint when using RME. RME
vesicles have a diameter of about 100 nm, which limits the amount of therapeutics that can be
internalized. Furthermore, lysosomal degradation may also prevent the treatment from being
successful.
Macropinocytosis is one of the clathrin-independent endocytotic mechanisms; it is an
actin-driven process. Unlike receptor-mediated endocytosis however, this process does not rely
directly on cargo/receptor interaction for its activation [20]. Therefore, macropinocytosis is a
non-specific internalization mechanism. It is a transient process in most cells and it can be
stimulated by the interaction between growth factors, such as the keratinocytes growth factor
(KGF) and epidermal growth factor (EGF), and their receptors [16, 21, 22]. This interaction
leads to an increase in actin polymerization that will result in cell membrane extensions called
ruffles. Falling back of these ruffles on the plasma membrane results on the formation of vesicles
called macropinosomes, which are characterized for being large, uncoated and leaky vesicles
[23-25].
Many of the innate characteristics of macropinocytosis make it an interesting targeted
mechanism to look into for targeted therapy. As mentioned above, macropinocytosis is nonselective; therefore, it can indiscriminately internalize molecules that are bound to the cell
membrane without the need for a specific cargo/receptor interaction. Consequently, the
interaction between a growth factor and its receptor resulting in enhanced macropinocytosis can
cause the uptake of multiple molecules bound on the cells surface [26]. In addition, the leaky
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nature of macropinosomes allows for the diffusion of the uptaken molecules to the cytoplasm
avoiding endosomal entrapment.
Having learned in the previous chapter that ELPs interact with heparan sulfate on the cell
surface, it makes us reason that this interaction may assist in the internalization of ELP fusion
molecules by allowing them to be bound to the cell surface for macropinocytosis to act on them.
In addition, we reasoned that a growth factor fused to ELPs could result in enhancement of
macropinocytosis. Therefore, this chapter deals with the use a heterogeneous nanoparticle
consisting of (KLAKLAK)2-ELP and KGF-ELP, figure 3.5. This multifunctional nanoparticle
allows for the selective enhancement of macropinocytosis in cells overexpressing the
keratinocyte growth factor receptor (KGFR). At the same time, due to the ELP domain, many of
these nanoparticles will be bound on the cell surface of the cell; therefore, many of them could
be internalized. Once inside the cell, the (KLAKLAK) 2-ELP fusion will cause cell death due to
mitochondrial depolarization as described in the previous chapter.
3.5 KGF-ELP Fusion Selectively Enhances Macropinocytosis
3.5.1 Materials and Methods
Fetal bovine serum (FBS) and Dulbecco modified Eagle Medium (DMEM) were
purchased from Life Technologies. The restriction enzymes and other enzymes used for cloning
were purchased from New England Biolabs (Ipswich, MA). H292, A549, H1650, H23, and
HCC827 cells were kindly donated by Dr. Haura from Moffit Cancer Center. CRCL2522,
fibroblasts, were purchased from ATCC (Manassas, VA). Human Small Airway Epithelial Cells
(SAEC) cells were kindly donated by Dr. Narasaiah Kolliputi from the Department of Internal
Medicine at USF Health. Growth factors and apoptotic peptide genes were purchased from
GenScript (Piscataway, NJ). The miniprep and gel extraction kits were purchased from
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QIAGEN. The reagents for real-time polymerase chain reaction (RT-PCR) were purchased from
Bio-Rad.
3.5.1.1 Synthesis of KGF-ELP
The PUC57 plasmids containing the genes (VPGVG)5 , (VPGVG)2VPGCG(VPGVG)2 ,
and KGF were purchased from Genscript (Piscataway, NJ). The V40C2 encoding gene was made
using recursive direction ligation method as described previously [27]. The KGF gene was
excised using PflMI and Bgll enzymes. This gene was then run on a 0.08% agarose gel and
extracted using QIAquick Gel Extraction Kit. The restriction enzyme PflMI linearized the
pUC19 vector containing the ELP sequence and the excised KGF gene was cloned in frame with
the ELP gene. This resulted in the pUC19 vector containing the KGF-ELP fusion protein gene
flanked by pfIMI and BgII sites. The sequences encoding for the fusion protein was then
removed from the pUC19 vector using pflMI and BgII enzymes and recovered by gel extraction
as explained above. After extraction, this gene was cloned in a modified pET25b+ expression
vector through SfiI site. This vector was modified to incorporate a SfiI cloning site for the
cloning of the fusion protein.
The pET25b+ vector containing the fusion protein gene was transformed into BLRD
competent cells through heat shock at 42 oC. A starting culture of 50 ml was inoculated overnight
and added to a 1 L culture the next day. The 1 L culture was then grown overnight and
subsequently purified by inverse transition cycling as described previously [28]. Figure 3.2
shows a representation of the genes for KGF and ELP and the production of the fusion KGFELP.
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3.5.1.2 Cell Culture
Cells were cultured in a humidified incubator at 37 0C and 5% CO2. Cells were seeded on
24 or 48-well plates until they were approximately 70% confluent. CRL-2522 (non-malignant
human foreskin fibroblast), A549 (human lung carcinoma), H292 (human lung carcinoma),
HCC827 (human lung adenocarcinoma), H23 (human lung adenocarcinoma), and H1650 (human
lung adenocarcinoma) were grown in DMEM supplemented with 10% FBS and 1% AA
(Complete Medium). SAEC were cultured in airway epithelial cell basal medium (PCS-300-030)
supplemented with Small Airway Epithelial Cell Growth Kit (PCS-301-040).
3.5.1.3 Internalization of KGF-ELP
Cells (HCC827) were treated for 24 Hrs. with 50 μM of KGF-ELP. After the treatment,
cells were fixed with 2.5% glutaraldehyde in 100 mM phosphate buffer at pH 7. Following
fixation, standard embedding protocol for resin section was followed. TEM imaging was
performed at Electron Microscopy Core Lab in the Interdisciplinary Science Building at the
University of South Florida. Figure 3.3 shows the internalized KGF-ELP.
3.5.1.4 Labeling of the Fusion Proteins
The cysteines present in the ELP sequence were labeled using maleimide chemistry for
the particle internalization experiments. Fluorescein-5-maleimide (AnaSpec Inc cat # 81405) was
mixed with the fusion proteins. The mixture was placed on an orbital shaker and incubated at
room temperature for 2 hours. Unconjugated fluorescein was removed by a series of hot and cold
cycles on a bench top centrifuge ran at a speed of 20000g for 10 minutes each time. The
supernatant was discarded after the hot spin and an equal amount of cold sterile PBS was added.
This mixture was spun at 4 0C and the supernatant was collected while the pellet was discarded.
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This formed one complete cycle of inverse temperature cycling. At least 5 cycles were
performed to remove of all the unconjugated Fluorescein.
3.5.1.5 Fusion Protein Internalization Assay
Cells (50,000/well) were seeded in 24-well plates and cultured as described above. They
were let grow until they were about 70% confluent and were treated with the indicated
treatments. For analysis, cells were washed twice with ice-cold PBS and were trypsinized using
0.25% trypsin (100 μl). Cells were pelleted and re-suspended in 300 μl of PBS containing 50
-diamidino-2phenylindole (DAPI) to allow exclusion of nonviable cells. The cells were analyzed using flow
cytometry and either the percent of fluorescent cells or the average intensity was quantified and
reported.
3.5.1.6 Dextran Assay
Twenty-four hours after the indicated treatment, dextran tetramethylrhodamine (Life
Technolo
cytometry analysis, cells were washed at least five times with ice-cold PBS. The steps described
above for flow analysis were then followed; however, trypan blue was not added.
3.5.1.7 Gene Expression Using RT-PCR
Cells (500,000/well) were seeded on 6-well plates and let grow to about 80% confluency.
RNA was isolated using the SV Total RNA isolation System (Promega cat # Z3100). cDNA
synthesis was done using iScript cDNA synthesis Kit from BIO-RAD (cat # 1708890) following
manufacturer’s protocol. RT-PCR was performed using BIO-RAD C1000 Thermal Cycler. The
following primers were used for the KGFR cDNA amplification: forward primer
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CAATTATATAGGGCAGGCCAACCAG and reverse primer AAGAAGACCCCTATGCAGTAAATGG.
3.5.1.8 Live/Dead Assay
Cells were seeded and treated with the indicated treatments for 3 days. After their
respective treatments, ethidium homodimer-1 (Life Technologies cat # E1169) was added to
each well to a final concentration of 4uM. Cells were then incubated for 1 hour at 37 oC. After the
incubation time, cells were washed twice with PBS to remove floating cells. NucBlue (Life
Technologies R37605) was then added for 20 minutes to stain nuclei, followed by two washes
with PBS. Eight random pictures were taken per well using the EVOS fluorescence microscope
(10X magnification). Pictures were taken in different channels (blue, green, red) and overlay.
Live/dead cell discrimination was performed using image J. A macro was created using the
functions split channel, threshold, and cell counter to count the total number of live cells (blue)
in each picture. Dead cells that were not removed after the washes were stained red or magenta
(blue and red); adjusting the threshold for the picture being analyzed easily isolated these cells.
Therefore, the final count of cells per picture only included live cells.
3.5.1.9 Statistical Analysis
For statistical significance, the p value was calculated using ANOVA single factor. P
values < 0.05 were considered significant. The reported errors indicate the ±SEM.
3.5.2 Results
3.5.2.1 KGF-ELP Enhances Internalization of (KLAKLAK)2-ELP in KGFR Overexpressing Cells
Macropinocytosis is a non-specific internalization process that results from cell ruffling;
furthermore, this process can be enhanced by growth factors [21]. Therefore, we reasoned that a
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treatment that includes growth factors could selectively enhance macropinocytosis in growth
factor receptor expressing cells. Earlier work has reported the overexpression of the keratinocyte
growth factor receptor (KGFR) in lung cancer cells [8]. Consequently, we used RT-PCR to
measure the expression of this receptor in several cell types including five lung cancer cell lines
and two noncancerous cell lines (Figure 3.4). We selected A549 cells for subsequent experiments
since they had the highest expression of this receptor. Our lab has previously synthesized the
fusion comprising of KGF and ELP, KGF-ELP, this fusion is bioactive and self-assembles into
nanostructures [28]. In order to test our hypothesis of selective enhancement of macropinocytosis
we created heterogeneous particles comprising of KGF-ELP and (KLAKLAK)2-ELP (Figure
3.5); the internalization analysis was carried out using flow cytometry. The results clearly show
that the heterogeneous particles containing (KLAKLAK)2-ELP improved (KLAKLAK)2-ELP
uptake by 21 folds compared to homogeneous particles consisting of (KLAKLAK)2-ELP only
(Figure 3.6). Since adding KGF-ELP to the (KLAKLAK)2-ELP formulation results in an
increased number of particles, we compared the uptake to homogeneous particles containing
similar concentration of (KLAKLAK)2-ELP as well as heterogeneous particles comprising of
non-functionalized ELP and (KLAKLAK)2-ELP (Figure 3.6). These data clearly suggest that
inclusion of KGF-ELP in the NP formulation improved the uptake of (KLAKLAK)2-ELP in
KGFR overexpressing cells. To further demonstrate the role of KGF-ELP in targeted
internalization, we compared the (KLAKLAK)2-ELP uptake in fibroblasts, which do not express
the KGFR. Indeed, the increase in (KLAKLAK)2-ELP uptake induced by the inclusion of KGFELP was not observed in fibroblasts (Figure 3.7).
We further wanted to demonstrate the direct relation between KGF-ELP treatment and
enhanced macropinocytosis. To accomplish this task, macropinosome formation was quantified
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after a 24 Hr. treatment with 1μM, 10μM or 50μM of KGF-ELP on A549 cells. Fluorescent
pictures were taken for visual representation (Figure 3.8). The results were quantified using flow
cytometry. Our data clearly suggest a dose dependent effect on macropinosome formation in
A549 cells (Figure 3.9). To show that this effect is selective, fibroblasts were also treated with
50μM of KGF-ELP as described above. The results showed no increase in macropinosome
formation (Figure 3.10). Combined, the results clearly imply that KGF-ELP induces
macropinocytosis selectively in KGFR expressing cells.
3.5.2.2 KGF-ELP Improves the Cytotoxic Effect of (KLAKLAK)2-ELP in KGFR
Overexpressing Cells
After showing that a formulation containing KGF-ELP improved the internalization of
(KLAKLAK)2-ELP in KGFR overexpressing cells, we tested if this higher internalization would
translate to targeted cytotoxicity. While there was no effect on fibroblasts, the combination
treatment resulted in about 35 % cell death in cells that had very little KGFR expression (Figure
3.11). Interestingly, the combination treatment resulted in nearly 50% to 70 % cell death in high
KGFR expressing cell lines (Figure 3.11, A549, HCC827, and H1650). These data show that the
combination treatment of KGF-ELP and (KLAKLAK)2-ELP resulted in significantly higher cell
death in high KGFR expressing cell.
3.6 Discussion and Summary
Targeted therapy is increasingly becoming popular for the treatment of lung cancer.
Currently, growth factor receptor tyrosine kinase inhibitors that target highly expressed growth
factor receptors in lung cancer are used for treatment [29]. Here, we describe an approach of
targeting lung cancer cells by exploiting the malignant processes that are inherent to them.
Specifically, we report the development of two chimeric fusion proteins namely (KLAKLAK)2-
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ELP and KGF-ELP that self-assemble into nanoparticles. In chapter 2 we showed that
(KLAKLAK)2-ELP nanoparticles are internalized by cancer cells resulting in cell death. This
internalization occurs via macropinocytosis and is mediated by the interaction of the ELP
domain with cell surface heparan sulfate proteoglycans (HSPG). In this chapter, we further show
that KGF-ELP selectively enhances macropinocytosis in high Keratinocyte Growth Factor
Receptor (KGFR) expressing cancer cells. Finally, heterogeneous NPs comprising of KGF-ELP
and (KLAKLAK)2-ELP selectively kill high KGFR expressing lung cancer cells with very little
impact on normal cells.
Macropinocytosis is enhanced by several growth factors [30, 31]. Therefore, growth
factors can be used to target high growth factor receptor expressing lung cancer cells [8, 32].
Indeed, our data demonstrate that macropinocytosis can be enhanced in KGFR over expressing
cells using the KGF-ELP fusion protein. This led to an increase in (KLAKLAK) 2-ELP
internalization by KGF-ELP only in cells overexpressing the KGFR. This uncovers the
opportunity to selectively deliver therapeutics using growth factor induced macropinocytosis.
While non-targeted macropinocytosis has been described for the delivery of lytic peptides or NPs
using cell penetration peptides [33], no studies describe the use of the keratinocyte growth factor
to achieve targeted delivery through macropinocytosis. Macropinocytosis is beneficial over the
commonly described receptor mediated internalization approaches that usually involve clathrincoated endocytosis. Firstly, macrop
efficient internalization of several nanoparticles in one macropinosome [31]. Since,
macropinosomes are inherently leaky, it allows rapid release of the nanoparticles in the cytosol
escaping lysosomal degradation [34]. Finally, receptor mediated endocytosis results in the
formation of one vesicle per ligand/receptor whereas in macropinocytosis once one nanoparticle
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binds to the receptor it will result in the uptake of several nanoparticles in the vicinity of the cells
due to cell surface ruffling induced by the growth factor; thereby, increasing efficiency of
uptake. It is to be noted that this process involves enhancing the process of macropinocytosis
through growth factor signaling as opposed to blocking it, which is in contrast to previous
approaches. Therefore, care needs to be taken in using this strategy, as there might be some
unwanted cancer enhancing effect due to growth factor receptor signaling.
In summary, in this chapter we have taken advantage and expanded on the findings in the
previous chapter. Previously we demonstrated that (KLAKLAK)2-ELP is internalized by cells
through the process of macropinocytosis. Furthermore, the ELP domain also becomes critical
since it facilitates the (KLAKLAK) 2-ELP nanoparticles to be bound to the cell surface; a step
that is required for macropinocytosis. Since macropinocytosis can be stimulated by growth
factors; in this chapter, we selectively enhanced macropinocytosis and the uptake of
(KLAKLAK)2-ELP in KGFR overexpressing lung cancer cells using the fusion KGF-ELP.
While we have focused on the delivery of the mitochondriotoxic peptide (KLAKLAK) 2, this
approach can easily be expanded to other peptides, imaging agents, or drugs thereby having
broad applications in cancer as well as intracellular drug delivery.
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Figure 3.1 Representation of clathrin-independent and clathrin-dependent endocytosis [35].
Right figure represents clathrin-independent endocytosis while left represent clathrin-dependent
endocytosis.
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Figure 3.2 Representation of the KGF-ELP purification and self-assemble property. Top,
representation of the KGF gene, ELP genes, and their translation to the fusion (KLAKLAK) 2ELP. Bottom, illustration of the phase transition property of the fusion above and below its
transition temperature (Tt).
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Figure 3.3 Internalization of KGF-ELP as seen by TEM. HCC827 cells were treated for 24 Hrs. with 50 μM of KGF-ELP; they were
then prepared and analyzed as described in the materials and methods section. The red arrows show the location of the KGF-ELP
nanoparticle.
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Figure 3.4 KGFR expression in lung cancer and normal cells. RT-PCR was used to determine the
Keratinocyte growth factor receptor (KGFR) expression in different cell lines. Normal lung cells
(SAEC), cancerous lung cells (H292, H1650, A549, HCC827, H23), and normal skin cells
(fibroblast) were tested for KGFR expression level. Cells were cultured in 6 well plates; once
they were about 90% confluent, their total RNA was extracted and cDNA was produced as
described in the material section. The results were normalized to Primary Small Airway
Epithelial cells (SAEC).
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Figure 3.5 Representation of the heterogeneous nanoparticle comprising of KGF-ELP and
(KLAKLAK)2-ELP.

55

Figure 3.6 Enhanced internalization of (KLAKLAK)2-ELP assisted by KGF-ELP in KGFR
overexpressing cells. A549 cells were treated for 24 Hrs. with four different formulations to test
for improved internalization due to KGF-ELP. Since nanoparticle formation, which also
improves internalization, is dependent on concentration, equimolar treatments in the absence of
KGF-ELP were also included. Labeled (KLAKLAK)2-ELP (10 μM) was used in all treatments.
The analysis was carried out using flow cytometry. Trypan blue was used in the sample
suspensions before analysis to prevent the inclusion of particles bound on the cell surface in the
analysis. These experiments were repeated two times with triplicates. * indicates p < 0.05 when
compared to (KLAKLAK)2-ELP (10μ).
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Figure 3.7 KGF-ELP does not improve internalization of (KLAKLAK) 2-ELP in low KGFR
expressing cells. Fibroblasts were treated with either labeled (KLAKLAK)2-ELP (10μ) or a
combination of labeled (KLAKLAK)2-ELP (10μ) and KGF-ELP (10μ) as described above. The
analysis was carried out as described above. These experiments were repeated two times with
triplicates. * indicates p < 0.05 when compared to (KLAKLAK)2-ELP (10μ).
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Figure 3.8 Dose-dependent enhancement of macropinosome formation in KGFR overexpressing cells. A549 cells were treated with
varying concentrations of KGF-ELP (1 μM, 10 μM, and 50 μM). After 24 Hrs., dextran tetramethylrhodamine was added for 1 Hr.
before analysis. Fluorescent picture were taken at 10x magnification.
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Figure 3.9 Quantification of macropinosome formation in A549 cells after KGF-ELP treatment.
A549 cells were serum starved for 24 Hrs. and then treated for 24 Hrs. with different
concentration of KGF-ELP (1μM, 10μM or 50μM). After treatment, rhodamine-labeled dextran
was added for 1 Hr. and cells were washed at least 5 times with ice cold PBS before analysis
using flow cytometry. Treatments were normalized to the control (no treatment). These
experiments were repeated two times with triplicates. * indicates p < 0.05 when compared to
control (no treatment).
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Figure 3.10 Quantification of macropinosome formation in fibroblast cells after KGF-ELP
treatment. Fibroblasts were treated with 50μM of KGF-ELP following the steps described in
figure 3.9; they were then analyzed by flow cytometry also following the aforementioned steps.
These experiments were repeated two times with triplicates. * indicates p < 0.05 when compared
to control (no treatment).
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Figure 3.11 Cytotoxic effect of (KLAKLAK)2-ELP is higher in KGFR overexpressing cells
when KGF-ELP is present. Fibroblasts, SAEC, H23, H292, A549, H1650 and HCC827 cells
were serum starved for 24 Hrs. and then treated for 36 Hrs. with (KLAKLAK)2-ELP (10μM)
combined with KGF-ELP (10μM). After treatment, cells were analyzed with a life/dead assay
and quantified using image J. The treatments were normalized to their respective control (no
treatment). These experiments were repeated two times with triplicates. * indicates p < 0.05
when compared to control (no treatment).
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CHAPTER 4: INHIBITION OF GLYCOLYSIS AS A POSSIBLE CANCER THERAPY

4.1 Introduction
The enzyme phosphoglycerate mutase (PGM) has recently received much attention
because it is the point at which glycolysis and anabolic biosynthesis are coordinated; this is done
through the conversion of 3-phosphoglycerate (3PG) to 2-phosphoglycerate (2PG). PGM is
activated by the phosphorylation of the histidine 11 (H11). In this chapter we show the synthesis
of a fusion comprising of a peptide, KLVLIRHGESAW, derived from PGM and elastin like
polypeptides (ELPs), PGM-ELP. The PGM domain in PGM-ELP comprises the H11 and a few
more peptides from PGM; therefore, it acts as a competitive inhibitor for the phosphorylation of
the PGM enzyme; the ELP domain will provide stability. Furthermore, we explore the cytotoxic
effect of having multiple copies of the PGM peptide fused to ELP, (PGM)4-ELP, where the
number indicates the number of PGM peptide copies in the fusion.
4.2 Glycolysis and the Phosphoglycerate Mutase (PGM) Enzyme
One of the hallmarks of cancer is the uncontrolled proliferation and growth of cells. The
formation of one cell is a very complex process that requires energy as well as the synthesis of
macromolecules such as phospholipids, amino acids, and nucleic acids [1]. Energy in the form of
ATP can be produced in two different areas of the cells and in the presence (aerobic) or not
(anaerobic) of oxygen. ATP can be produced in the cytosol via glycolysis; this is very inefficient
ATP producing pathway since it happens in the absence of oxygen; during glycolysis a net of 2
ATP molecules are synthesized. ATP can also be synthesized within the mitochondria; this
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process occurs in the presence of oxygen via oxidative phosphorylation; this process is called
cell respiration. In the mitochondria, a net of 36 ATP molecules are obtained from a single
molecule of glucose [2]. One could conclude that cancer cells, because of the high-energy
requirements needed for proliferation, would favor aerobic respiration. However, several studies
have consistently shown that the glycolytic rate in cancer cells is higher that in normal cells [3,
4]; therefore, targeting glycolysis is an attractive alternative [5-7].
Several studies have argued that higher ATP production is not likely the reason for high
glycolytic rate; instead, they claimed that glycolysis provides the building blocks required for the
synthesis of macromolecules (DNA, RNA, lipids, and proteins) needed for giving rise to new
cells [8, 9]. Others maintained that glycolysis is responsible for faster ATP production needed for
proliferating cells. Regardless of the conclusion of either of the arguments, it is clear that the
inhibition of glycolysis can prove fruitful in the development of a targeted cancer therapy.
Glycolysis is a catabolic pathway through which a molecule of glucose is converted to
two molecules of pyruvate through ten enzyme-catalyzed steps (Figure 4.1). Pyruvate is then
taken into the mitochondria for energy production. During the different glycolytic steps,
molecules that are the building block for macromolecules are synthetized. After glucose is
internalized, it is phosphorylated forming glucose-6-phosphate (G6P). G6P participates in the
pentose phosphate pathway that gives rise to nucleic acid synthesis. Glyceraldehyde-3-phosphate
(G3P), an intermediate of glycolysis, participates in the synthesis of lipids. Also, the glycolytic
intermediate 3-phosphoglycerate (3PG) contributes to the synthesis of amino acids.
Due to the involvement of glycolysis in biosynthesis, there are several possible targets in
the glycolytic pathway that could result in proliferation and growth being halted [10-12]. Some
of them are already being explored. For example, the compound 2-Deoxyglucose (2-DG) is a
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glucose analog that reduces the phosphorylation of glucose by the enzyme hexokinase (HK) .
HK does not distinguish between 2-DG and glucose; therefore, the phosphorylation of the analog
by HK reduces the amount of phosphorylated glucose available for glycolysis [6, 13]. This
blocks the pentose phosphate pathway resulting in the synthesis of ribose, precursor of nucleic
acids, being halted. Furthermore, because 2-DG acts in the early steps of glycolysis, it also
disrupt other anabolic reactions occurring downstream from the pentose phosphate pathway such
as lipid and protein synthesis. Several studies have reported the positive results associate with 2DG when used alone [14] and in combination with other therapeutic agents [15, 16]; however,
development of resistance has also being reported [17, 18]. Moreover, other studies have argued
that the mechanism by which 2-DG inhibits cell growth need to be further studied since its
mechanism of action is not fully understood [19].
Other groups have focus on the enzyme phosphoglycerate mutase (PGM) as a possible
target to block glycolysis [20]. This enzyme is considered a useful target for cancer treatment
because it is located at the branching point between glycolysis and anabolic biosynthesis [21-23],
both required for cell growth and proliferation. In addition, PGM has been found to be
overexpress in some cancers [24, 25]. This enzyme catalyzes the conversion of 3phosphoglycerate (3PG) to 2-phosphoglycerate (2PG). Inhibition of PGM will result in increase
3PG and decrease 2PG, both of which have detrimental consequences for the cell. Accumulation
of 3PG results in inhibition of the enzyme 6-phosphogluconate dehydrogenase (6PGD) [22]; this
enzyme is part of the pentose phosphate pathway, which is responsible for the synthesis of
nucleotide precursors. The reduction of 2PG reduces the activity of the enzyme
phosphoglycerate dehydrogenase enzyme (PHGDH), preventing the synthesis of serine from
3PG and further increasing the amount of 3PG. Furthermore, decrease in 2PG results in
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reduction of phosphoenolpyruvate (PEP) and its conversion to pyruvate carried out by the
enzyme pyruvate kinase (PK) isoform 2 (PKM2) which is stimulated by serine. In short,
inhibiting this enzyme will have a dual effect; it will result in the reduction of ATP due to
decrease in pyruvate synthesis (catabolic reaction) and inhibition of anabolic biosynthesis.
Previous work used a synthetic peptide (Leu-Ile-Arg-His-Gly-Glu or LIRHGE) derived
from the PGM domain that included a histidine amino acid that is phosphorylated when PGM is
in its active form [21]. This sequence was functionalized by the addition of a cell penetrating
peptide (CPP) to increase its internalization. The results show a decrease in cell growth;
however, the effect of the peptide dissipated after approximately three days and cancer cells
continued proliferating. The study suggested that this could be due to degradation of the peptide.
4.3 Fusion PGM-ELP
4.3.1 Materials and Methods
Fetal bovine serum (FBS) and Dulbecco modified Eagle Medium (DMEM) were
purchased from Life Technologies. The restriction enzymes and other enzymes used for cloning
were purchased from New England Biolabs (Ipswich, MA). H292, A549, H1650, H23, and
HCC827 cells were kindly donated by Dr. Haura from Moffit Cancer Center. CRCL2522,
fibroblasts, were purchased from ATCC (Manassas, VA). Human Small Airway Epithelial Cells
(SAEC) cells were kindly donated by Dr. Narasaiah Kolliputi from the Department of Internal
Medicine at USF Health. The PGM gene was purchased from GenScript (Piscataway, NJ). The
miniprep and gel extraction kits were purchased from QIAGEN. The reagents for RT-PCR were
purchased from Bio-Rad.
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4.3.1.1 Synthesis of PGM-ELP and (PGM)4-ELP
The PUC57 plasmids containing the genes (VPGVG)5 , (VPGVG)2VPGCG(VPGVG)2 ,
and KLVLIRHGESAW (PGM sequence) were purchased from Genscript (Piscataway, NJ). The
V40C2 encoding gene was made using recursive direction ligation method as described
previously [26]. The PGM gene was excised using PflMI and Bgll enzymes. This gene was then
run on a 0.08% agarose gel and extracted using QIAquick Gel Extraction Kit. The restriction
enzyme PflMI linearized the pUC19 vector containing the ELP sequence and the excised PGM
gene was cloned in frame with the ELP gene. This resulted in the pUC19 vector containing the
PGM-ELP fusion protein gene flanked by pfIMI and BgII sites. The sequences encoding for the
fusion protein was then removed from the pUC19 vector using pflMI and BgII enzymes and
recovered by gel extraction as explained above. After extraction, this gene was cloned in a
modified pET25b+ expression vector through SfiI site. This vector was modified to incorporate a
SfiI cloning site for the cloning of the fusion protein.
The pET25b+ vector containing the fusion protein gene was transformed into BLRD
competent cells through heat shock at 42 oC. A starting culture of 50 ml was inoculated overnight
and added to a 1 L culture the next day. The 1 L culture was then grown overnight and
subsequently purified by inverse transition cycling as described previously [27]. Figure 4.2
shows a representation of the genes for PGM and ELP and the production of the fusion PGMELP. The fusion (PGM)4-ELP was synthesized as described above, but four copies of the PGM
gene were cloned in frame with the ELP gene resulting in the fusion (PGM)4-ELP.
4.3.1.2 Cell Culture
Cells were cultured in a humidified incubator at 37 0C and 5% CO2. Cells were seeded on
24 or 48-well plates until they were approximately 70% confluent. CRL-2522 (non-malignant
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human foreskin fibroblast), A549 (human lung carcinoma), H292 (human lung carcinoma),
HCC827 (human lung adenocarcinoma), H23 (human lung adenocarcinoma), and H1650 (human
lung adenocarcinoma) were grown in DMEM supplemented with 10% FBS and 1% AA
(Complete Medium). SAEC were cultured in airway epithelial cell basal medium (PCS-300-030)
supplemented with Small Airway Epithelial Cell Growth Kit (PCS-301-040).
4.3.1.3 Live/Dead Assay
Cells were seeded and treated only once for 1,2 ,or 6 days as indicated. The media was
changed every two to three days but the treatment was not repeated. After their respective
treatments, ethidium homodimer-1 (Life Technologies cat # E1169) was added to each well to a
final concentration of 4uM. Cells were then incubated for 1 hour at 37 oC. After the incubation
time, cells were washed twice with PBS to remove floating cells. NucBlue (Life Technologies
R37605) was then added for 20 minutes to stain nuclei, followed by two washes with PBS. Eight
random pictures were taken per well using the EVOS fluorescence microscope (10X
magnification). Pictures were taken in different channels (blue, green, red) and overlay.
Live/dead cell discrimination was performed using image J. A macro was created using the
functions split channel, threshold, and cell counter to count the total number of live cells (blue)
in each picture. Dead cells that were not removed after the washes were stained red or magenta
(blue and red); adjusting the threshold for the picture being analyzed easily isolated these cells.
Therefore, the final count of cells per picture only included live cells.
4.3.1.4 2-Phosphoglycerate (2PG) Assay
Cells (H292) were seeded in six-well plates (500,000/well). After 24 Hrs. they were
treated for 48 Hrs. with either 10 μM or 100 μM of PGM-ELP. After treatment they were lysed
following the assay protocol. The 2-phosphoglycerate colorimetric assay kit (BioVision cat #
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k778-100) was used to measure the concentration of 2PG and the protocol was fo llowed as
described in the kit.
4.3.1.5 Labeling of the Fusion Proteins
The cysteines present in the ELP sequence were labeled using maleimide chemistry for
the particle internalization experiments. Fluorescein-5-maleimide (AnaSpec Inc cat # 81405) was
mixed with the fusion proteins. The mixture was placed on an orbital shaker and incubated at
room temperature for 2 hours. Unconjugated fluorescein was removed by a series of hot and cold
cycles on a bench top centrifuge ran at a speed of 20000g for 10 minutes each time. The
supernatant was discarded after the hot spin and an equal amount of cold sterile PBS was added.
This mixture was spun at 4 0C and the supernatant was collected while the pellet was discarded.
This formed one complete cycle of inverse temperature cycling. At least 5 cycles were
performed to get rid of all the unconjugated Fluorescein.
4.3.1.6 Fusion Protein Internalization Assay
Cells (50,000/well) were seeded in 24-well plates and cultured as described above. They
were let grow until they were about 70% confluent and were treated with the indicated
treatments. For analysis, cells were washed twice with ice-cold PBS and were trypsinized using
0.25% trypsin (100 μl). Cells were pelleted and re-suspended in 300 μl of PBS containing 50
-diamidino-2phenylindole (DAPI) to allow exclusion of nonviable cells. The cells were analyzed using flow
cytometry and either the percent of fluorescent cells or the average intensity was quantified and
reported.
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4.3.1.7 Statistical Analysis
For statistical significance, the p value was calculated using ANOVA single factor. P
values < 0.05 were considered significant. The reported errors indicate the ±SEM.
4.3.2 Results
4.3.2.1 The Fusion PGM-ELP Interferes with the Phosphoglycerate Mutase Enzyme
The glycolytic enzyme phosphoglycerate mutase (PGM) controls both the glycolytic
pathway and the synthesis of macromolecules needed for cell growth and proliferation. Previous
works showed that a using a peptide derived from the PGM domain could act as a competitive
inhibitor for this enzyme and inhibit cell proliferation. However, this inhibition was transient and
lasted for about 3 days; the study concluded this occurred because of the peptide degradation
[21]. We reasoned that ELPs could increase stability of the peptide since previous works have
shown that ELPs are resistant to degradation [28]. Therefore, we purified the fusion PGM-ELP
and first tested for its bioactivity. Our results clearly show that the fusion PGM-ELP is bioactive
and causes cell death at high concentration after 24 and 48 Hrs. (Figures 4.3, 4.4 and 4.5).
Furthermore, since PGM-ELP competes with the phosphorylation of PGM (Figure 4.6), a
decreased in PGM phosphorylation would result in the 2PG concentration decrease. Indeed, we
found that treatments with PGM-ELP decreased the amount of 2PG (Figure 4.7) after 48 hours.
Combined, these results suggest that PGM-ELP is bioactive and causes cell death by competing
with an enzyme (PGM) in the glycolytic pathway.
We wanted to test the cytotoxicity of PGM-ELP in different cells lines. Therefore, lung
cancer cells (A549, H23, HCC827, H292), connective tissue cells (Fibroblasts, Fb), and normal
lung cells (Small airway epithelial cells, SAEC) were tested for PGM-ELP cytotoxicity. Cells
were treated as describe in the material and methods section with 50 μM of PGM-ELP. After 6
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days, PGM-ELP displays cytotoxic effects in all cell lines; however, its effect is noticeable
higher in the lung cancer cells (Figure 4.8). Furthermore, to test if the ELP domain assisted in
improving the killing effect of the PGM domain, cells were also treated with the PGM peptide
(50 μM) and the results were compared to the PGM-ELP 50 μM treatment (Figure 4.9). The
results clearly show that the fusion PGM-ELP is much more cytotoxic than the PGM peptide.
4.3.2.2 The Internalization of PGM-ELP is Improved by KGF-ELP
We reasoned that the internalization and therefore cytotoxic effect of PGM-ELP could be
enhanced if the endocytotic mechanism of macropinocytosis is stimulated. As described in
chapter 3, the fusion KGF-ELP induces macropinocytosis in keratinocyte growth factor receptor
(KGFR) overexpressing cells (A549); therefore, an heterogeneous nanoparticle comprising of
PGM-ELP and KGF-ELP (Figure 4.10) could improve the internalization of PGM-ELP in A549
cells. Indeed, our results clearly show that including KGF-ELP in the treatment resulted in an
approximately 20 fold increase when compared to the PGM-ELP 10 μM treatment (Figure 4.11).
However, since adding 5 μM of KGF-ELP changes the molarity of the treatment, we also
included and 15 μM PGM-ELP treatment; this still shows more than a 2-fold increase when
KGF-ELP is part of the treatment (Figure 4.11). In addition, the treatment consisting of
unfunctionalized ELP and PGM-ELP shows no increased in PGM-ELP internalization when
compared to the 15 μM PGM-ELP (Figure 4.11). Altogether, the data implies that KGF-ELP
improves internalization of PGM-ELP.
4.3.2.3 KGF-ELP Enhances the Cytotoxic Effect of PGM-ELP in KGFR Overexpressing
Cells
Having found that KGF-ELP increases PGM-ELP internalization in A549 cells, we tested
if this would translate to higher cytotoxicity in these cells. Cells were treated as described in the
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material and methods section and a concentration of PGM-ELP that did not cause cytotoxicity
after 3 days was used (50 μM). The results show clearly that after 6 days PGM-ELP is cytotoxic
and about 55% of cells have died (Figure 4.12). Interestingly, the treatment that included the
fusion KGF-ELP caused almost 95% of cell death (Figure 4.12). These results further confirmed
that the inclusion of KGF-ELP improves internalization and cytotoxicity of PGM-ELP.
Cells with different levels of KGFR expression (chapter 3) were treated with the
formulations PGM-ELP (50 μM) or PGM-ELP (50 μM) and KGF-ELP (20 μM). All cells,
except A549, show no improvement by the inclusion of KGF-ELP in the treatment (Figure 4.13).
A549, having the highest KGFR expression, shows a definite increase in cells death. Altogether,
the results propose that the presence of KGF-ELP adds selectivity to the treatment.
4.3.2.4 The Addition of Multiple PGM Domains to ELP Enhances Cytotoxicity
Having observed that PGM-ELP is cytotoxic, we reasoned that this effect could be
boosted if multiple PGM domains are fused to ELP. To this end, we added four PGM domains to
ELP, (PGM)4-ELP. We treated HCC827 cells, as described above, with varying concentrations
of (PGM)4-ELP (10 μM, 50 μM, and 100 μM) for 3 days. Interestingly, all concentrations
induced cell death (Figure 4.14) after this short period of time. Furthermore, Figure 4.15 clearly
shows that the same treatment (50 μM) of (PGM)4-ELP and PGM-ELP induced approximately
the same amount of cells death but (PGM)4-ELP only took 3 days compared to the 6 days
needed for PGM-ELP.
4.4 Discussion and Summary
The tumor microenvironment is very complex; a single tumor has cells with different
genotypes; therefore, a single therapeutic might not be enough to prevent the tumor from
growing. Many have looked into targeting glycolysis since higher than normal glycolytic rate has
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been observed in cancer cells regardless of their genotype. Herein, we report the synthesis of the
fusion protein PGM-ELP that inhibits glycolysis resulting in cell death. Furthermore, we show
that the heterogeneous nanoparticle comprising of PGM-ELP and KGF-ELP enhances
internalization and cytotoxic effect of PGM-ELP in KGFR overexpressing cells. Finally, a fusion
consisting of multiple copies of the PGM domain fuse to ELP, (PGM)4-ELP, improves the
fusion cytotoxic effect.
Previous works have demonstrated that using an amino acid sequence from the
phosphoglycerate mutase enzyme (PGM) that encompasses the histidine 11 (H11) prevents cell
proliferation. However, the promising observations are only temporary; the study suggested the
degradation of the peptide as the cause. We synthesized the fusion PGM-ELP; the PGM domain
in this fusion is derived from the PGM enzyme and encompasses H11. The ELP would provide
stability by preventing degradation. Our results clearly show this fusion to be bioactive and
causing cell death after three days but only at high concentrations (100 μM). Furthermore, the
cytotoxic effect is also observed in various cell lines after 6 days, even at low concentrations (50
μM). We believe this observation is because of the number of H11 sites available. The lower
concentration offers less number of H11 sites; therefore, glycolytic inhibition takes longer. This
could explain why a 50 μM treatment does not cause cell death after 3 days, but it does after 6
days. In addition, since the cells were treated only once during the 6-day period, it is reasonable
to conclude that the PGM-ELP was still present within the cells. Therefore, the ELP domain
provided stability to the fusion. Moreover, the treatment with the PGM peptide was much less
cytotoxic than the fusion PGM-ELP. We reasoned that this could be attributed to the stability
imparted by the ELP domain as well as the interaction between the ELP domain and the cell
surface. This interaction permits the PGM-ELP fusion to be bound to the cell surface; therefore,
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allowing cells to have more access to the molecules compared to the unbound PGM peptide. Our
data also demonstrates that the fusion PGM-ELP acts by affecting glycolysis; this can be
concluded from the approximately 60% reduction in the concentration of 2PG in the treated
cells. 2PG is the product of the PGM enzyme; therefore, a drastic reduction in its concentration
can safely be attributed to an inhibited PGM enzyme.
Additionally, our data shows that not all cells responded equally to the PGM-ELP
treatment. The most obvious difference is observed in groups, cancer cell group versus normal
cell group. One reason why cancer cells responded better to the treatment can be attributed to
their inherently more active nature; cancer cells exhibit higher levels of macropinocytosis
compared to normal cells. Another plausible explanation is that cancer cells are highly dependent
on glycolysis; therefore, inhibiting this pathway may have more impact in cancer than in normal
cells.
Our results show that the addition of the KGF-ELP fusion to the treatment resulted in
higher PGM-ELP uptake in KGFR overexpressing cells. Some of the internalization can be
attributed to the higher concentration of the treatment that included KGF-ELP. However, when
the same concentration treatments are compared, there still exist an increase in PGM-ELP uptake
when KGF-ELP is part of the formulation. This can be associated to the enhancement of
macropinocytosis due to the interaction between KGF-ELP and the KGFR as demonstrated in
chapter 3. Furthermore, the increase in internalization also resulted in improved cytotoxicity in
cells overexpressing the KGFR. Our data clearly shows that KGFR overexpressing cells
decreased by approximately 80% when compared to the formulation containing only PGM-ELP.
Previously, we hypothesized that the number H11 sites available may be the reason for
the lower concentration treatment (50 μM) to take effect after 6 days; therefore, we synthesized a
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fusion containing four H1 sites, (PGM)4-ELP. The results clearly display a dose dependent
cytotoxic effect. Interestingly, the killing effect was observed after only 3 days. Comparing the
HCC827 data for the 50 μM PGM-ELP treatment (6 days) and 50 μM (PGM)4-ELP treatment (3
days) , it becomes very apparent the improvement in efficiency and cytotoxicity due to the higher
number of H11 sites. The HCC827 6-day treatment resulted in an approximately 60% cell death
while the 3-day treatment resulted in about 70% cell death. Therefore, our data validates the idea
that increasing the number of H11 sites improves toxicity by PGM-ELP.
In summary, we have demonstrated that the fusion PGM-ELP induces cell death by
inhibiting glycolysis. Furthermore, this fusion seems to have a higher effect in cancer cells,
which could be related to their high dependence in glycolysis and/or their intrinsic more active
nature. We also showed that the heterogeneous nanoparticle comprising of KGF-ELP and PGMELP enhances the internalization and cytotoxic effect of PGM-ELP in KGFR overexpressing
cells. Lastly, our data suggests a correlation between the number of H11 sites and the efficacy of
the PGM-ELP; that is, (PGM)4-ELP is more efficient than PGM-ELP in terms of killing time
and percent of killing.
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Figure 4.1 Representation of the glycolytic pathway [29].
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Figure 4.2 Graphical representation of PGM-ELP synthesis and its self-assemble property. Top,
representation of the PGM gene, ELP genes, and their translation to the fusion PGM-ELP.
Bottom, illustration of the phase transition property of the fusion above and below its transition
temperature (Tt). The fusion is soluble below its T t and aggregates above its Tt.
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Figure 4.3 Phase contrast picture of the PGM-ELP treatment. A549 cells were treated for 3 days; after which, phase contrast
microscope pictures were taken. Top row show 4X magnification and bottom row 10X magnification, the columns show the different
concentrations used (10 μM, 50 μM, and 100 μM). The control received no treatment.
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Figure 4.4 Quantification of live cells after a 24 Hr. treatment with PGM-ELP. A549 were
seeded and quantified as described in M&M. All the treatments have been normalized to the
control.
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Figure 4.5 Quantification of live cells after a 48 Hr. treatment with PGM-ELP. A549 were
seeded and quantified as described in M&M. All the treatments have been normalized to the
control.
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Figure 4.6 Graphical representation of the intracellular effect of PGM-ELP on the glycolytic
pathway. Briefly, the phosphorylating complex that activates the PGM enzyme will also
phosphorylate the PGM-ELP fusion. This reduces the availability of activated PGM, which
results in increase 3-PG and decrease 2-PG. Higher 3-PG concentration blocks 6PGD; therefore,
glycolysis and macromolecule synthesis (Ribose-5-phosphate) are inhibited.
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Figure 4.7 2PG intracellular concentration in H292 cells after PGM-ELP treatment. A 2PG
colorimetric assay was used to show inhibition of the PGM enzyme. H292 cells were treated
with PGM-ELP (10 μM and 100 μM) for 48 Hrs. After the treatment the concentration of 2PG
was measured and normalized to the control (no treatment).
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Figure 4.8 Quantification of live cells in various cell types after PGM-ELP treatment. Various cell lines (cancerous and non
cancerous) were treated with 50 μM of PGM-ELP. The media was changed every two days after treatment and the cells were not
retreated. Six days after treatment, the quantification was done as described in the M&M section.
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Figure 4.9 PGM peptide and PGM-ELP treatments. Cells were treated with 50 μM of either
PGM peptide or PGM-ELP for 6 days. The media was changed every two days, but the
treatments were not repeated. Clearly, the data shows that PGM-ELP is more cytotoxic than the
PGM peptide. Treatments were normalized to their respective PGM peptide treatment.
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Figure 4.10 Graphical representation of the heterogeneous nanoparticle comprising of KGF-ELP
and PGM-ELP.
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Figure 4.11 Normalized internalization of PGM-ELP in the presence and absence of KGF-ELP.
A549 cells were treated with the described formulations for 24 Hrs. All formulations consist of
10 μM labeled PGM-ELP. The intensity relates to the amount of labeled PGM-ELP internalized
per cell. The quantification was carried out by flow cytometry. * = p < 0.05. Number in parenthesis represent the concentration in μM.
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Figure 4.12 KGF-ELP enhances the PGM-ELP cytotoxic effect in KGFR overexpressing cells.
A549 were treated once and the media was changed every two days. Six days after treatment, the
quantification was done as described in the M&M section; the results were normalized to the
control (no treatment). * = p < 0.05.Number in parenthesis represent the concentration in μM.
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Figure 4.13 KGF-ELP enhances PGM-ELP cytotoxicity only in KGFR overexpressing cells. Various cell lines (cancerous and non
cancerous) were treated with 50 μM of PGM-ELP and 20 μM of KGF-ELP. The media was changed every two days after treatment
and the cells were not retreated. Six days after treatment, the quantification was done as described in the M&M section. Results were
normalized to the PGM-ELP treatment.
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Figure 4.14 (PGM)4-ELP induces killing in a dose dependent manner. HCC827 cells were
treated for 3 days with the (PGM)4-ELP fusion with the shown concentrations. The results were
normalized to the control (no treatment). * = p < 0.05.
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Figure 4.15 (PGM)4-ELP is more cytotoxic than PGM-ELP. HCC827 cells were treated with the
same concentrations of (PGM)4-ELP and PGM-ELP for 3 and 6 days, respectively. The graph
clearly shows approximately the same percent of live cells after treatment when each is
compared to its respective control (no treatment).
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CHAPTER 5: SUMMARY, CONCLUSIONS AND FUTURE WORK

5.1 Summary and Conclusions
In this doctoral research, we have shown the selective enhancement of macropinocytosis
for the treatment of lung cancer. This is a novel approach that takes advantage of an endocytotic
mechanism that is inherently present in cancer cells, macropinocytosis. Macropinocytosis is
transient and can be stimulated by the interaction between growth factors and their receptors on
the cell surface. Herein, we used the keratinocyte growth factor receptor (KGFR) as the target for
our treatment; this receptor has been reported to be overexpressed in lung cancer. We used the
fusion comprising of the keratinocyte growth factor (KGF) and elastin like polypeptides (ELPs),
KGF-ELP, previously synthesized in our lab to enhance macropinocytosis in KGFR
overexpressing cells. After this selective enhancement, a mitochondriotoxic fusion peptide
comprising of (KLAKLAK)2 and ELP, (KLAKLAK)2–ELP, was delivered causing
mitochondrial depolarization and subsequent cell death. Finally, we used a glycolytic inhibitory
peptide and fuse it to ELPs, PGM-ELP. This peptide was also delivered selectively to KGFR
overexpressing cells using the KGF-ELP fusion; this also resulted in selective killing.
In chapter 2, we found that the fusion (KLAKLAK) 2-ELP is mitochondriotoxic without
the need to be functionalized; the nanoparticle conformation provided by the ELP backbone was
enough to cause the internalization and cytotoxicity of the fusion. Furthermore, cell death occurs
via mitochondrial depolarization and swelling. We found that the mechanism of internalization
of (KLAKLAK)2-ELP is macropinocytosis; we believe the interaction between the ELP domain
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of the fusion and heparan sulfate on the cell membrane allows for the proximity required for
macropinocytosis to act on the (KLAKLAK)2-ELP nanoparticles.
In chapter 3, we have taken advantage and expanded on the findings in the previous
chapter. Previously we demonstrated that (KLAKLAK) 2-ELP is internalized by cells through the
process of macropinocytosis. Furthermore, the ELP domain also becomes critical since it
facilitates the (KLAKLAK)2-ELP nanoparticles to be bound to the cell surface; a step that is
required for macropinocytosis. Since macropinocytosis can be stimulated by growth factors; in
this chapter, we selectively enhanced macropinocytosis and the uptake of (KLAKLAK) 2-ELP in
KGFR overexpressing lung cancer cells using the fusion KGF-ELP. While we have focused on
the delivery of the mitochondriotoxic peptide (KLAKLAK) 2, this approach can easily be
expanded to other peptides, imaging agents, or drugs thereby having broad applications in cancer
as well as intracellular drug delivery.
In chapter 4, we have demonstrated that the fusion PGM-ELP induces cell death by
inhibiting glycolysis. Furthermore, this fusion seems to have a higher effect in cancer cells,
which could be related to their high dependence in glycolysis and/or their intrinsic more active
nature. We also showed that the heterogeneous nanoparticle comprising of KGF-ELP and PGMELP enhances the internalization and cytotoxic effect of PGM-ELP in KGFR overexpressing
cells. Lastly, our data suggests a correlation between the number of H11 sites and the efficacy of
the PGM-ELP; that is, (PGM)4-ELP is more efficient than PGM-ELP in terms of killing time
and percent of killing.
5.2 Future Work
The work we presented in this dissertation shows an innovative approach for targeted
therapy; therefore, we believe it lays the groundwork for its advancement. Furthermore, due to
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the adaptability of this system, it can easily be expanded to treat other types of cancers that may
overexpress different growth factor receptors than the one we targeted such as the epidermal
growth factor receptor as it occurs in breast and pancreatic cancers.
In addition, we focused on the selective delivery of cytotoxic peptides that aimed at either
the mitochondria or glycolysis. However, due to the simplicity of our system, it is possible the
formation of multivalent nanoparticles that could selectively aim at multiple targets. For
instance, instead of targeting either the mitochondria or glycolysis, a multivalent nanoparticle
could disrupt the mitochondria while blocking glycolysis; this could have synergistic effects on
the treatment of cancer. Moreover, this targeted system is not limited to the delivery of cytotoxic
peptides. Due to the cysteine amino acid that forms part of our ELP construct, using simple
maleimide chemistry allows the conjugation of cancer therapeutics that can be selectively
delivered by macropinocytosis. This could result in improved intracellular concentration of the
therapeutics, prevention of endosomal entrapment and lysosomal degradation.
Finally, the application of selectively stimulating macropinocytosis is not limited to the
treatment of cancer. We believe that it can be further exploited in other fields such as in gene
therapy. In this field, the targeted delivery of a gene is critical since unwanted gene insertion or
inactivation may have severe consequences on the patient. Therefore, a selective delivery of the
gene by macropinocytosis can ensure the therapy reaches its target and minimizes side effects.
Overall, we envision that further study of our work can result in improving current
targeted treatments for cancer. Additionally, we see the possibility of expanding this research to
other fields for which selective delivery is paramount.
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Appendix A: List of Abbreviations
(KLAKLAK)2 .......................KLAKLAKKLAKLAK
2-DG ...................................... 2-Deoxyglucose
2PG ........................................2-Phosphoglycerate
3PG ........................................3-Phosphoglycerate
6PGD......................................6-phosphogluconate dehydrogenase
A .............................................Alanine
A549 .......................................Adenocarcinoma cells, non-small cell lung cancer
ATP ........................................Adenosine triphosphate
CCCP .....................................Carbonylcyanide m- chlorophenylhydrazone
CO2 .........................................Carbon dioxide
Cyt c .......................................Cytochrome c
DAPI ......................................4',6-diamidino-2-phenylindole
DLS ........................................Dynamic light scattering
DNA .......................................Dioxyribose nucleic acid
E .............................................Glutamate
EGF ........................................Epidermal growth factor
EGFR .....................................Epidermal growth factor receptor
ELP ........................................Elastin like polypeptide
ETC ........................................Electron transport chain
Fb ...........................................Fibroblast
FBS ........................................Fetal bovine serum
FITC .......................................Fluorescein isothiocyanate
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G3P ........................................Glyceraldehyde-3-phosphate
G6P ........................................Glucose-6-phosphate
Gly..........................................Glycine
H .............................................Histidine
H11 .........................................Histadine at location 11
H1650 .....................................Adenocarcinoma cells, non-small cell lung cancer
H23 .........................................Adenocarcinoma cells, non-small cell lung cancer
H292 .......................................Adenocarcinoma cells, non-small cell lung cancer
HCC827 .................................Adenocarcinoma cells, non-small cell lung cancer
HGF........................................Hepatocyte growth factor
HK ..........................................Hexokinase
HSPG .....................................Heparan sulfate proteoglycan
I ..............................................Isoleucine
ITC .........................................Inverse temperature cycling
K .............................................Lysine
KGF........................................Keratinocyte growth factor
KGFR .....................................Keratinocyte growth factor receptor
L .............................................Leucine
LCST ......................................Lower critical solution temperature
M&M .....................................Materials and methods
mAb........................................Monoclonal antibodies
MET .......................................MET proto-oncogene
NSCLC ...................................Non-Small Cell Lung Cancer
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O2 ...........................................Oxygen
PBS ........................................Phosphate buffered-saline
PEP .........................................phosphoenolpyruvate
PGM .......................................Phosphoglycerate mutase
PHGDH ..................................phosphoglycerate dehydrogenase enzyme
PK ..........................................Pyruvate kinase
PKM2 .....................................Pyruvate kinase isoform 2
Pro ..........................................Proline
R .............................................Arginine
RME .......................................Receptor mediated endocytosis
RNA .......................................Ribonucleic acid
RT-PCR..................................Real-time polymerase chain reaction
S .............................................Serine
SAEC .....................................Small airway epithelial cells
SEM .......................................Square error of the mean
TEM .......................................Transmission electron microscopy
TKI .........................................Tyrosine kinase inhibitor
Tt ............................................Transition temperature
Val ..........................................Valine
W ............................................Tryptophan
X .............................................Guest amino acid residue
μM ..........................................Micromolar
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The permission below is for material in Chapters 2 and 3.
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